Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Benzodiazepines intake...

    Benzodiazepines intake may increase miscarriage risk

    Written by Medha Baranwal Baranwal Published On 2019-04-10T19:20:58+05:30  |  Updated On 10 April 2019 7:20 PM IST
    Benzodiazepines intake may increase miscarriage risk

    POLAND: Benzodiazepines are the drugs used for the treatment of anxiety during pregnancy. A new study has however found that women taking benzodiazepines for anxiety treatment are at significantly increased risk for spontaneous abortion.


    These are the results of a large-scale study presented at the European Psychiatric Association (EPA) 2019 Congress.

    The study was conducted by Anick Bérard, from the Faculty of Pharmacy, University of Montreal, Quebec, Canada, and colleagues, who evaluated more than 27,000 cases of spontaneous abortion and 1.3 million unaffected pregnancies during at 17-year period from an ongoing study.


    The investigators gathered data from the ongoing Quebec Pregnancy Cohort, which covers 422,066 pregnancies between January 1998 and December 2015. They excluded women who had previously taken benzodiazepines and those who underwent induced or planned abortions. They included 27,149 women who experienced clinically detected, spontaneous abortion between the 6th and 19th week of pregnancy (mean, 13 weeks' gestation) during the study period.


    Each case patient was then matched with up to five randomly selected women who had not experienced spontaneous abortion, yielding a control group of 134,305 women.


    Also Read: Defect in sperms may be cause of recurrent abortions, finds study

    Key findings of the study include:

    • Incident use of benzodiazepines during pregnancy was associated with an 85% increase in the risk of having a clinically detected spontaneous abortion between the 6th and 19th week of pregnancy.

    • Although the duration of action of the drug did not seem to affect risk, there was an increase in risk with increasing equivalent dose, so that women taking the highest doses had a more than 2.5-fold increased risk for spontaneous abortion.

    • Women who experienced spontaneous abortion were significantly more likely to have used benzodiazepines for the first time during pregnancy than other women, at 1.4% vs 0.6% (odds ratio adjusted for comedication use and indication, 1.85).

    • Women who experienced spontaneous abortion were also more likely than control women to be aged 35 years or older at gestation and to have been diagnosed with mood and anxiety disorders or insomnia in the 12 months prior to pregnancy.

    • On analyzing benzodiazepine exposure more closely, they found that, with respect to the risk for spontaneous abortion, associations were similar for short-acting benzodiazepines and for long-acting drugs (adjusted odds ratios, 1.81 and 1.73, respectively). Short-acting drugs were defined as those having a duration of action of up to 24 hours.

    • There appeared to be a dose-response effect with respect to a mean daily diazepam equivalent dose of benzodiazepines across the cohort.

    • Certain benzodiazepines, such as diazepam (multiple brands), temazepam (multiple brands), bromazepam (multiple brands), alprazolam (multiple brands), and clonazepam (Klonapine, Roche), appeared to be more strongly associated with spontaneous abortions than other benzodiazepines.


    Also Read: Once prescribed, 25% of elderly become dependent on benzodiazepines: JAMA

    According to Bérard, benzodiazepine use seems to be associated with an increase in spontaneous abortion, regardless of type, regardless of the duration of action, and there seems to be a dose-response effect." "This equates to an increase in the absolute rate of spontaneous abortion from around 6% in the background population to around 10%," she explains.

    benzodiazepinesbromazepamclonazepamdiazepamEPAEuropean Psychiatric AssociationMiscarriagePregnancypregnancy lossspontaneous abortiontemazepam

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok